

## Biovica's DiviTum®TKa included in new UK breast cancer study

**DiviTum®TKa has been selected to be included in a new prospective study of women with hormone receptor positive metastatic breast cancer. The aim of including DiviTum®TKa in the study is to investigate if this marker can be used for disease monitoring during treatment with a CDK4/6 inhibitor, which in combination with an aromatase inhibitor is considered standard of care for this subgroup of patients.**

The hypothesis is that routine imaging can be delayed until predefined levels of biomarker progression is detected. The aim is to establish a biomarker algorithm, which includes DiviTum®TKa and other biomarkers, that safely can define response to therapy or stable disease and also predict disease progression. DiviTum®TKa accurately correlates with disease status and can be a useful tool in this respect.

“Our study aims to optimise the monitoring of patients, utilising circulating biomarkers to avoid unnecessary imaging exams. We have chosen to include DiviTum for analysis of TK activity as accurate measurements of cell proliferation rate is likely to be important in this setting. DiviTum has documented ability to provide precise prognostic and efficacy monitoring capabilities and we look forward to see results that can potentially enhance monitoring options in metastatic breast cancer”, said Dr. Sacha J. Howell, FRCP, PhD and Principal Investigator of the study.

The study will collect blood samples before treatment initiation and during therapy with the aim to include approximately 100 patients in the UK and Sweden.

“We look forward to collaborate with Christie Hospital in Manchester and other clinics in the study in UK and Sweden in this exciting study, where we believe the results can potentially contribute to a more personalised approach also regarding radiological follow-up for metastatic breast cancer patients”, said Anders Rylander, CEO of Biovica.

Link to study [NCT04597580](https://clinicaltrials.gov/ct2/show/study/NCT04597580)

### Contact

---

Anders Rylander, CEO

Phone: +46-18-444 48 35

E-mail: [anders.rylander@biovica.com](mailto:anders.rylander@biovica.com)

### Biovica – Treatment decisions with greater confidence

---

Biovica develops and commercializes blood-based biomarker assays to evaluate efficacy of cancer treatments. Biovica's assay DiviTum® measure cell proliferation by detecting a biomarker in the blood stream. The assay has successfully demonstrated its capabilities to early evaluate therapy effectiveness in several clinical trials. The first application for DiviTum is monitoring of treatment for patients with metastatic breast cancer. Biovica's vision is that all cancer patients will get an optimal treatment from day one. Biovica collaborates with world-leading cancer institutes and pharmaceutical companies. DiviTum is CE-marked and registered with the Swedish Medical Products Agency. Biovica's shares are traded on the Nasdaq First North Growth Market (BIOVIC B). FNCA Sweden AB is the company's Certified Adviser, [info@fnca.se](mailto:info@fnca.se), +46 8 528 00 399. For more information please visit: [www.biovica.com](http://www.biovica.com).

### **Attachments**

---

[Biovica's DiviTum®TKa included in new UK breast cancer study](#)